Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abiraterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 16/20 | 1.00 |
| ▸ | AR known ✓ | P10275 | 1/20 | 0.71 |
| ▸ | CYP21A2 | P08686 | 6/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 3/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abiraterone SCHEMBL16383633 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL17474701 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL20459184 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL23924960 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL8736929 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL25074918 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL13272100 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL19724576 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL22414103 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 | |
| Abiraterone SCHEMBL15700283 | 1.00 | CYP17A1 (1.00) | CYP17A1CYP21A2CYP11B1CYP3A4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 24639 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746850-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | Ferring BV (NL) | 2026-05-27 | — | — | EP | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3946313-B1 | ONVANSERTIB FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | CARDIFF ONCOLOGY INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-120504685-B | Prodrug structure with ROS signal response performance, and preparation method and application thereof | Rehabilitation University (CN) | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4744666-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-122060013-A | L-valine abiraterone p-toluenesulfonic acid crystal form and preparation method thereof | 山东新时代药业有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122060014-A | Salt of abiraterone derivative and preparation method thereof | 山东新时代药业有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-1556058-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESTETROL DERIVATIVES FOR USE IN CANCER THERAPY | Pantarhei Bioscience B.V. (NL) | 2005-07-27 | — | — | EP | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| WO-2004037269-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESTETROL DERIVATIVES FOR USE IN CANCER THERAPY | PANTARHEI BIOSCIENCE B.V. (NL) | 2004-05-06 | — | — | WO | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| EP-0633893-B1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BTG INT LTD (GB) | 1999-11-24 | — | — | EP | claimed |
| JP-2742331-B2 | — | — | 1998-04-22 | — | — | JP | claimed |
| EP-0633893-A1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BRITISH TECHNOLOGY GROUP LTD (GB) | 1995-01-18 | — | — | EP | claimed |
| WO-1993020097-A1 | 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-10-14 | — | — | WO | claimed |